Vol. 3 No. 4 (2023)
Reimbursement Reviews

Lumasiran (Oxlumo)

decorative image

Published April 24, 2023

Key Messages

  • CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses lumasiran (Oxlumo), 94.5 mg/0.5 mL lumasiran (as lumasiran sodium), subcutaneous injection.
  • Indication: For the treatment of primary hyperoxaluria type 1 to lower urinary oxalate levels in pediatric and adult patients.